TIM‑3 inhibits PDGF‑BB‑induced atherogenic responses in human artery vascular smooth muscle cells

Lian,Chong; Wang,Zhecun; Qiu,Jiacong; Jiang,Baohong; Lv,Junbing; He,Rongzhou; Liu,Ruiming; Li,Wen; Wang,Jinsong; Wang,Shenming

doi:10.3892/mmr.2020.11167

TIM‑3 inhibits PDGF‑BB‑induced atherogenic responses in human artery vascular smooth muscle cells

Authors:
- Chong Lian
- Zhecun Wang
- Jiacong Qiu
- Baohong Jiang
- Junbing Lv
- Rongzhou He
- Ruiming Liu
- Wen Li
- Jinsong Wang
- Shenming Wang
View Affiliations

Affiliations: Division of Vascular Surgery, Guangdong Key Engineering Laboratory for Diagnosis and Treatment of Vascular Disease, The First Affiliated Hospital, Sun Yat‑sen University, Guangzhou, Guangdong 510080, P.R. China, Laboratory of General Surgery, Guangdong Key Engineering Laboratory for Diagnosis and Treatment of Vascular Disease, The First Affiliated Hospital, Sun Yat‑sen University, Guangzhou, Guangdong 510080, P.R. China
Published online on: May 21, 2020 https://doi.org/10.3892/mmr.2020.11167
Pages: 886-894
Copyright: © Lian et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Increasing evidence suggests that T‑cell immunoglobulin and mucin domain 3 (TIM‑3) displays anti‑atherosclerotic effects, but its role in vascular smooth muscle cells (VSMCs) has not been reported. The present study aimed to investigate the function of TIM‑3 and its roles in human artery VSMCs (HASMCs). A protein array was used to investigate the TIM‑3 protein expression profile, which indicated that TIM‑3 expression was increased in the serum of patients with lower extremity arteriosclerosis obliterans disease (LEAOD) compared with healthy individuals. Immunohistochemistry and western blotting of arterial tissue further revealed that TIM‑3 expression was increased in LEAOD artery tissue compared with normal artery tissue. Additionally, platelet‑derived growth factor‑BB (PDGF‑BB) displayed a positive correlation with TIM‑3 expression in HASMCs. TIM‑3 decreased the migration and proliferation of PDGF‑BB‑induced HASMCs, and anti‑TIM‑3 blocked the effects of TIM‑3. The effect of TIM‑3 on the proliferation and migration of HASMCs was further investigated using LV‑TIM‑3‑transduced cells. The results revealed that TIM‑3 also inhibited PDGF‑BB‑induced expression of the inflammatory factors interleukin‑6 and tumor necrosis factor‑α by suppressing NF‑κB activation. In summary, the present study revealed that TIM‑3 displayed a regulatory role during the PDGF‑BB‑induced inflammatory reaction in HASMCs, which indicated that TIM‑3 may display anti‑atherosclerotic effects.

View Figures

View References

1	Criqui MH, Vargas V, Denenberg JO, Ho E, Allison M, Langer RD, Gamst A, Bundens WP and Fronek A: Ethnicity and peripheral arterial disease: The San Diego Population Study. Circulation. 112:2703–2707. 2005. View Article : Google Scholar : PubMed/NCBI
2	Fowkes FG, Rudan D, Rudan I, Aboyans V, Denenberg JO, McDermott MM, Norman PE, Sampson UK, Williams LJ, Mensah GA and Criqui MH: Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: A systematic review and analysis. Lancet. 382:1329–1340. 2013. View Article : Google Scholar : PubMed/NCBI
3	Crotty S: T Follicular Helper cell biology: A decade of discovery and diseases. Immunity. 50:1132–1148. 2019. View Article : Google Scholar : PubMed/NCBI
4	Yu E, Hsu HY, Huang CY and Hwang LC: Inflammatory biomarkers and risk of atherosclerotic cardiovascular disease. Open Med (Wars). 13:208–213. 2018. View Article : Google Scholar : PubMed/NCBI
5	Kim J, Zhang L, Peppel K, Wu JH, Zidar DA, Brian L, DeWire SM, Exum ST, Lefkowitz RJ and Freedman NJ: Beta-arrestins regulate atherosclerosis and neointimal hyperplasia by controlling smooth muscle cell proliferation and migration. Circ Res. 103:70–79. 2008. View Article : Google Scholar : PubMed/NCBI
6	Lee J and Kang H: Hypoxia Promotes vascular smooth muscle cell proliferation through microRNA-mediated suppression of Cyclin-dependent kinase inhibitors. Cells. 8(pii): E8022019. View Article : Google Scholar : PubMed/NCBI
7	Heldin CH and Westermark B: Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev. 79:1283–1316. 1999. View Article : Google Scholar : PubMed/NCBI
8	Liu K, Liu C and Zhang Z: lncRNA GAS5 acts as a ceRNA for miR-21 in suppressing PDGF-bb-induced proliferation and migration in vascular smooth muscle cells. J Cell Biochem. 120:15233–15240. 2019. View Article : Google Scholar : PubMed/NCBI
9	Hu W and Huang Y: Targeting the platelet-derived growth factor signalling in cardiovascular disease. Clin Exp Pharmacol Physiol. 42:1221–1224. 2015. View Article : Google Scholar : PubMed/NCBI
10	Zofková I: Osteoporosis and aterosclerosis-is there any pathogenetic association? Cas Lek Cesk. 146:246–250. 2007.(In Czech). PubMed/NCBI
11	Hartman J and Frishman WH: Inflammation and atherosclerosis: A review of the role of interleukin-6 in the development of atherosclerosis and the potential for targeted drug therapy. Cardiol Rev. 22:147–151. 2014. View Article : Google Scholar : PubMed/NCBI
12	Song C, Wang Y, Cui L, Yan F and Shen S: Triptolide attenuates lipopolysaccharide-induced inflammatory responses in human endothelial cells: Involvement of NF-κB pathway. BMC Complement Altern Med. 19:1982019. View Article : Google Scholar : PubMed/NCBI
13	Ponte E and Ursu HI: Overt and subclinical hypothyroidism and atherosclerotic arteriopathy of the lower limbs (clinical and subclinical). Rom J Endocrinol. 31:71–79. 1993.PubMed/NCBI
14	Hou N, Zhao D, Liu Y, Gao L, Liang X, Liu X, Gai X, Zhang X, Zhu F, Ni M, et al: Increased expression of T cell immunoglobulin- and mucin domain-containing molecule-3 on natural killer cells in atherogenesis. Atherosclerosis. 222:67–73. 2012. View Article : Google Scholar : PubMed/NCBI
15	Liang X, Xu Z, Yuan M, Zhang Y, Zhao B, Wang J, Zhang A and Li G: MicroRNA-16 suppresses the activation of inflammatory macrophages in atherosclerosis by targeting PDCD4. Int J Mol Med. 37:967–975. 2016. View Article : Google Scholar : PubMed/NCBI
16	Foks AC, Ran IA, Wasserman L, Frodermann V, Ter Borg MN, de Jager SC, van Santbrink PJ, Yagita H, Akiba H, Bot I, et al: T-cell immunoglobulin and mucin domain 3 acts as a negative regulator of atherosclerosis. Arterioscler Thromb Vasc Biol. 33:2558–2565. 2013. View Article : Google Scholar : PubMed/NCBI
17	Qiu MK, Wang SC, Dai YX, Wang SQ, Ou JM and Quan ZW: PD-1 and Tim-3 pathways regulate CD8+ T cells function in atherosclerosis. PLoS One. 10:e01285232015. View Article : Google Scholar : PubMed/NCBI
18	Hu W, Wang M, Yin H, Yao C, He Q, Yin L, Zhang C, Li W, Chang G and Wang S: MicroRNA-1298 is regulated by DNA methylation and affects vascular smooth muscle cell function by targeting connexin 43. Cardiovasc Res. 107:534–545. 2015. View Article : Google Scholar : PubMed/NCBI
19	Zhang N, Zhang M, Liu RT, Zhang P, Yang CL, Yue LT, Li H, Li YK and Duan RS: Statins reduce the expressions of Tim-3 on NK cells and NKT cells in atherosclerosis. Eur J Pharmacol. 821:49–56. 2018. View Article : Google Scholar : PubMed/NCBI
20	Zhang F, Zhao J, Sun D and Wei N: miR-155 inhibits transformation of macrophages into foam cells via regulating CEH expression. Biomed Pharmacother. 104:645–651. 2018. View Article : Google Scholar : PubMed/NCBI
21	Bennett MR, Sinha S and Owens GK: Vascular smooth muscle cells in atherosclerosis. Circ Res. 118:692–702. 2016. View Article : Google Scholar : PubMed/NCBI
22	Maracle CX, Agca R, Helder B, Meeuwsen JAL, Niessen HWM, Biessen EAL, de Winther MPJ, de Jager SCA, Nurmohamed MT and Tas SW: Noncanonical NF-κB signaling in microvessels of atherosclerotic lesions is associated with inflammation, atheromatous plaque morphology and myocardial infarction. Atherosclerosis. 270:33–41. 2018. View Article : Google Scholar : PubMed/NCBI
23	Das M, Zhu C and Kuchroo VK: Tim-3 and its role in regulating anti-tumor immunity. Immunol Rev. 276:97–111. 2017. View Article : Google Scholar : PubMed/NCBI
24	Sánchez-Fueyo A, Tian J, Picarella D, Domenig C, Zheng XX, Sabatos CA, Manlongat N, Bender O, Kamradt T, Kuchroo VK, et al: Tim-3 inhibits T helper type 1-mediated auto- and alloimmune responses and promotes immunological tolerance. Nat Immunol. 4:1093–1101. 2003. View Article : Google Scholar : PubMed/NCBI
25	Huang SC, Wang M, Wu WB, Wang R, Cui J, Li W, Li ZL, Li W and Wang SM: miR-22-3p inhibits arterial smooth muscle cell proliferation and migration and neointimal hyperplasia by targeting HMGB1 in arteriosclerosis obliterans. Cell Physiol Biochem. 42:2492–2506. 2017. View Article : Google Scholar : PubMed/NCBI
26	Andrés V: Control of vascular cell proliferation and migration by cyclin-dependent kinase signalling: New perspectives and therapeutic potential. Cardiovasc Res. 63:11–21. 2004. View Article : Google Scholar : PubMed/NCBI
27	Zhang Y, Qian X, Sun X, Lin C, Jing Y, Yao Y, Ma Z, Kuai M, Lu Y, Kong X, et al: Liuwei Dihuang, a traditional Chinese medicinal formula, inhibits proliferation and migration of vascular smooth muscle cells via modulation of estrogen receptors. Int J Mol Med. 42:31–40. 2018.PubMed/NCBI
28	Hao B, Xiao Y, Song F, Long X, Huang J, Tian M, Deng S and Wu Q: Metformin-induced activation of AMPK inhibits the proliferation and migration of human aortic smooth muscle cells through upregulation of p53 and IFI16. Int J Mol Med. 41:1365–1376. 2018.PubMed/NCBI
29	Qiu MK, Wang SC, Tang Y, Pan C, Wang Y, Wang SQ, Quan ZW and Ou JM: Tim-3 inhibits low-density lipoprotein-induced atherogenic responses in human umbilical vein endothelial cells. Oncotarget. 8:61001–61010. 2017. View Article : Google Scholar : PubMed/NCBI
30	Ohira H, Tsutsui W and Fujioka Y: Are Short Chain Fatty Acids in Gut Microbiota defensive players for inflammation and atherosclerosis. J Atheroscler Thromb. 24:660–672. 2017. View Article : Google Scholar : PubMed/NCBI
31	Pant S, Deshmukh A, Gurumurthy GS, Pothineni NV, Watts TE, Romeo F and Mehta JL: Inflammation and atherosclerosis-revisited. J Cardiovasc Pharmacol Ther. 19:170–178. 2014. View Article : Google Scholar : PubMed/NCBI
32	Gliozzi M, Scicchitano M, Bosco F, Musolino V, Carresi C, Scarano F, Maiuolo J, Nucera S, Maretta A, Paone S, et al: Modulation of nitric oxide synthases by oxidized LDLs: Role in vascular inflammation and atherosclerosis development. Int J Mol Sci. 20(pii): E32942019. View Article : Google Scholar : PubMed/NCBI
33	Pan JX: LncRNA H19 promotes atherosclerosis by regulating MAPK and NF-κB signaling pathway. Eur Rev Med Pharmacol Sci. 21:322–328. 2017.PubMed/NCBI
34	Ge H, Tang H, Liang Y, Wu J, Yang Q, Zeng L and Ma Z: Rhein attenuates inflammation through inhibition of NF-κB and NALP3 inflammasome in vivo and in vitro. Drug Des Devel Ther. 11:1663–1671. 2017. View Article : Google Scholar : PubMed/NCBI
35	Lai JL, Liu YH, Liu C, Qi MP, Liu RN, Zhu XF, Zhou QG, Chen YY, Guo AZ and Hu CM: Indirubin inhibits LPS-induced inflammation via TLR4 abrogation mediated by the NF-κB and MAPK signaling pathways. Inflammation. 40:1–12. 2017. View Article : Google Scholar : PubMed/NCBI